BioVersys: Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)

13 April 2026

BioVersys press release

— BioVersys and partners publish in Nature Communications pre-clinical development data of AlpE (alpibectir and ethionamide), an innovative drug combination that overcomes drug-resistance to Mycobacterium tuberculosis (Mtb).
— Alpibectir is a potential first-in-class molecule for treating drug-resistant TB by targeting new bioactivation pathways exploited by ethionamide in Mtb.
— Pre-clinical data show that alpibectir potentiates ethionamide (Eto) bioactivation, resulting in rapid killing of the bacteria and restoring Eto susceptibility in resistant Mtb strains.
— AlpE, is currently being studied by BioVersys’ partner GSK in a pulmonary TB Phase 2b trial, expected to finalize recruitment by end of 2027, and by BioVersys in a TB meningitis Phase 2 trial that was recently initiated.

Read the full press release here.

 

Source: BioVersys

---

SEE ALSO:

• Bioengineering: AlpE Combo: New TB Treatment Breakthrough